MGNX News and Press, MacroGenics Inc. From 10/31/23

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial r...

2023-09-10 04:04:16 ET Summary MacroGenics specializes in antibody-based cancer treatments; strong financials and collaborations signal future growth. Despite a stock dip and revenue decrease, MacroGenics' non-dilutive capital strategy and diverse pipeline show promise. Given ...

2023-09-05 16:46:53 ET More on MacroGenics Seeking Alpha’s Quant Rating on MacroGenics Historical earnings data for MacroGenics Financial information for MacroGenics MacroGenics, Inc. 2023 Q2 - Results - Earnings Call Presentation MacroGenics, ...

ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc...

2023-08-19 07:40:00 ET Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer. Deciphera Pharmaceuticals (NASDAQ: DCPH) , Mirati Thera...

2023-08-10 12:33:41 ET Shares of MacroGenics (NASDAQ: MGNX) were up more than 24% as of 11:45 a.m. on Thursday after the biotech company announced second-quarter earnings. The stock is down more than 7% so far this year. MacroGenics focuses on antibody-based therapeutics for the...

2023-08-09 23:30:23 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q2 2023 Earnings Call Aug 09, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q2 2023 Earnings Call Transcript

2023-08-09 21:21:06 ET MacroGenics, Inc. (MGNX) Q2 2023 Earnings Conference Call August 09, 2023 04:30 PM ET Company Participants Jim Karrels - VP and CFO Scott Koenig - President and CEO Conference Call Participants Jonathan Chang - Leerink Partners ...

2023-08-09 16:09:41 ET MacroGenics press release ( NASDAQ: MGNX ): Q2 GAAP EPS of $0.92 beats by $1.43 . Revenue of $13.13M (-49.5% Y/Y) misses by $16.83M . For further details see: MacroGenics GAAP EPS of $0.92 beats by $1.43, revenue of $13.13M misses b...

Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data...